Advanced Search

Home > Journals > International Angiology > Past Issues > International Angiology 2016 August;35(4) > International Angiology 2016 August;35(4):365-8



A Journal on Angiology

Official Journal of the International Union of Angiology, the International Union of Phlebology and the Central European Vascular Forum
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899

Frequency: Bi-Monthly

ISSN 0392-9590

Online ISSN 1827-1839


International Angiology 2016 August;35(4):365-8


Novel oral anticoagulants in the treatment of cerebral venous thrombosis

Gergely FEHER 1, Zsolt ILLES 2, Samuel KOMOLY 3, David HARGROVES 4

1 Szigetvar Hospital, Szigetvár, Hungary; 2 University of Southern Denmark, Odense, Denmark; 3 University of Pecs, Pécs, Hungary; 4 William Harvey Hospital, Kent, UK

Cerebral venous thrombosis (CVT) is an uncommon cause of stroke with extremely diverse clinical features, predisposing factors, brain imaging findings, and outcome. Anticoagulation is the cornerstone of CVT management, however, it is not supported by high-quality evicence. Novel oral anticoagulants (NOACs) have been extensively studied in patients with deep vein thrombosis, pulmonary embolism and non-valvular atrial fibrillation. The aim of our work was to review the available evidence for NOACs in the treatment of CVT. Based on our literature search there is insufficient evidence to support the use of NOACs in CVT, although case series with rivaroxaban and dabigatran have showed promising results.

language: English


top of page